Skip to content

Fentanyl Ultra Low Doses Effects on the Nociceptive Threshold

Fentanyl Ultra Low Doses Effects on Human Volunteer's Nociceptive Threshold. Towards a Simple Pharmacological Test Able to Predict Pain Vulnerability, Post Operative Hyperalgesia Development Risk?

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00454259
Acronym
FENTANULD
Enrollment
48
Registered
2007-03-30
Start date
2007-03-01
Completion date
2007-08-01
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

Postoperative Hyperalgesia, Human volunteer, Fentanyl, Randomized Controlled Trial, Pain chronicisation, Predictive test

Brief summary

Exaggerated pain and hyperalgesia are major issues after surgery and can lead to chronic pain. Opioid are parts of pain sensitization processes but remain absolutely necessary in the intraoperative period. NMDA receptor antagonists succeed in reducing this pain sensitization process. Recent studies show that in pain and opioid-experienced rats (POER) fentanyl ultra low doses do not induce analgesia, as observed in naive rats, but hyperalgesia. This is the first demonstration that a drug can induce opposite effect depending on individual history. We also observed a strong correlation between this hyperalgesic response in POER and the intensity of hyperalgesia they develop later, after inflammatory or surgical pain. The main aim of this study is to measure the dose effect response to fentanyl "ultra low doses" on human volunteer's nociceptive threshold, to determine if such an opposite response profile can be revealed.

Detailed description

* Principal Objective : "Evaluate fentanyl "ultra low doses" effects on human volunteer's nociceptive threshold depending on their prior pain and opioid experience." * Secondary Objective : "Confirm the innocuousness of this test (the 3 "ultra low doses" used in this trial will be 10 to 1,000 fold lower than low doses use for anesthesia and analgesia) and to find the fentanyl ultra low dose that could be used to develop a pain sensitisation predictive test." * Study design : Bicentric, prospective, randomized, double-blind study. Inclusion criteria : In both groups: * 18-40 years old male volunteer * weight: 60 to 85 kg * ASA score: 1 * Informed consent obtained from the patient * Gender : Male In "operated" group: \- At least one history of peripheral surgery under general anesthesia with opioid in the past five years Exclusion criteria : In both groups: * The patient do not accept inclusion to the study * Drug or alcohol abuse history * Chronic use of analgesic drugs or history of chronic pain * Analgesic or opioid consumption within the 12hs preceding the fentanyl or placebo injection * Neurological and/or psychiatric disorder, inability to give informed consent * Psychological trauma within the two year preceding the inclusion * Any contraindication to fentanyl use * Use of any medication interacting with fentanyl * Exclusion period from the national healthy volunteer register * Gender : Female In "healthy" group: \- Any history of general anesthesia or surgery * Study plan: comparing two groups that only defer by their surgical and opioid prior experience and will receive three fentanyl ultra low doses (10 to 1,000 fold lower than low doses use for anesthesia and analgesia) and placebo (cross over administration, one week wash out period). * Number of subjects : 48

Interventions

DRUGFentanyl/Placebo injection

Ultra low dose intravenous injection

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

In both groups: * 18-40 years old male volunteer * Weight: 60 to 85 kg * ASA score: 1 * Informed consent obtained from the patient In "operated" group: * At least one history of peripheral surgery under general anesthesia with opioid in the past five years.

Exclusion criteria

In both groups: * The patients do not accept inclusion to the study * Drug or alcohol abuse history * Chronic use of analgesic drugs or history of chronic pain * Analgesic or opioid consumption within the 12hs preceding the fentanyl or placebo injection * Neurological and/or psychiatric disorder, inability to give informed consent * Psychological trauma within the two year preceding the inclusion * Any contraindication to fentanyl use * Use of any medication interacting with fentanyl * Exclusion period from the national healthy volunteer register In "healthy" group: * Any history of general anesthesia or surgery

Design outcomes

Primary

MeasureTime frame
Nociceptive threshold evaluated with sternal electronical Von Frey mechanical stimulation. The stimulation will increase until the volunteer presses a trigger when the stimulation becomes painful.5 min after injection, and every 15 min during 1 hour

Secondary

MeasureTime frame
Non invasive blood pressure (SBP, DBP), heart rate, respiratory rate, pulse oxymetry and cognitive functions evaluation (sedation score).all along the experimentation

Countries

France

Contacts

STUDY_DIRECTORPhilippe RICHEBE, Dr

University Hospital, Bordeaux

PRINCIPAL_INVESTIGATORGérard JANVIER, PHD

University Hospital, Bordeaux

PRINCIPAL_INVESTIGATORClaude DUBRAY, PHD

University Hospital, Bordeaux

PRINCIPAL_INVESTIGATORAlain ESCHALIER, PHD

University Hospital, Bordeaux

PRINCIPAL_INVESTIGATORjean DUALE CHRISTIAN, Dr

University Hospital, Bordeaux

PRINCIPAL_INVESTIGATORGisèle PICKERING, Dr

University Hospital, Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026